DSM-Firmenich stock: Citi raises target for DSM-Firmenich stock from EUR 106.00 to EUR 111.00
Published on 10/19/2026 at 16:07 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSRaised target and earnings date
- Citi raised its DSM-Firmenich target from EUR 106.00 to EUR 111.00 on September 25, 2026.
- The dividend yield stood at 2.31 percent on October 19, 2026.
- DSM-Firmenich stock costs EUR 108.63 at 4:00 p.m. CEST at Lang & Schwarz on October 19, 2026, 1.48 percent above the Xetra close of October 16, 2026 at EUR 107.05.
- The next earnings report is scheduled for February 18, 2027.
Citi raised its DSM-Firmenich price target from EUR 106.00 to EUR 111.00 on September 25, 2026, according to MarketWatch. The new target sits 2.18 percent above the Lang & Schwarz price of EUR 108.63 at 4:00 p.m. CEST on October 19, 2026, while the stock was 1.48 percent above the Xetra close of October 16, 2026 at EUR 107.05.
Dividend yield adds valuation context
The dividend yield stood at 2.31 percent on October 19, 2026. Market capitalization was EUR 26.5 billion, and the 52-week range ran from EUR 55.22 to EUR 108.90. The current price was 0.25 percent below that high, calculated from the Lang & Schwarz price and the matching range.
Price position and trading range
The intraday indication moved between EUR 106.40 and EUR 108.65 on October 19, 2026, with a bid of EUR 108.60 and an ask of EUR 108.65. The latest price therefore stood EUR 0.02 below the quoted day high. On October 19, 2026, shareholders elected Richard Ridinger as chairman, succeeding Thomas Leysen, as Manila Times reported.
Results date and peer comparison
TradingView lists February 18, 2027 as the next earnings date. That date gives investors a clear calendar marker after the September target revision and the October 19 leadership vote.
Comparison with peers
DSM-Firmenich: plus 1.48 percent, dividend yield 2.31 percent, market capitalization EUR 26.5 billion
Symrise (Xetra, EUR): plus 0.18 percent, P/E 37.41, market capitalization EUR 13.7 billion
Givaudan (SIX, CHF): plus 0.74 percent, P/E 29.31, market capitalization CHF 36.4 billion
Price remains near the yearly high
The market value and range place DSM-Firmenich near its 52-week high, while the target revision provides a separate dated valuation reference. The next earnings date is February 18, 2027.
DSM-Firmenich was trading at EUR 108.63 at Lang & Schwarz on October 19, 2026 at 4:00 p.m. CEST, up 1.48 percent versus the Xetra close of October 16, 2026 at EUR 107.05. The further course of trading is shown by the continuously updated real-time quote of DSM-Firmenich stock.
DSM-Firmenich market data
- Company: dsm-firmenich AG
- ISIN: CH1216478797
- Ticker: DSFIR
- Primary exchange: Euronext Amsterdam
- Price Lang & Schwarz (as of October 19, 2026, 4:00 p.m. CEST): EUR 108.63
- Change versus Xetra close: plus 1.48 percent
- Xetra close (October 16, 2026): EUR 107.05
- Market capitalization: EUR 26.5 billion (as of October 19, 2026)
- 52-week range: EUR 55.22-108.90 (as of October 19, 2026)
- Sector / Industry: Basic Materials / Specialty Chemicals
- Next earnings date: February 18, 2027
Market context: Market report AEX.
